Your browser doesn't support javascript.
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19.
Fhied, Cristina L; Tarhoni, Imad; Gerard, David; Lewin, Grant M; Moudgalya, Hita; Schneider, Jeffrey R; Borgia, Jeffrey A.
  • Fhied CL; Department of Anatomy & Cell Biology, Rush University Medical Center.
  • Tarhoni I; Department of Anatomy & Cell Biology, Rush University Medical Center.
  • Gerard D; Department of Anatomy & Cell Biology, Rush University Medical Center.
  • Lewin GM; Department of Anatomy & Cell Biology, Rush University Medical Center.
  • Moudgalya H; Department of Anatomy & Cell Biology, Rush University Medical Center.
  • Schneider JR; Department of Microbial Pathogens and Immunity, Rush University Medical Center.
  • Borgia JA; Department of Anatomy & Cell Biology, Rush University Medical Center; Department of Pathology, Rush University Medical Center; jeffrey_borgia@rush.edu.
J Vis Exp ; (180)2022 02 16.
Article in English | MEDLINE | ID: covidwho-1732305
ABSTRACT
Multiplex technologies for interrogating multiple biomarkers in concert have existed for several decades; however, methods to evaluate multiple epitopes on the same analyte remain limited. This report describes the development and optimization of a multiplexed immunobead assay for serological testing of common immunoglobulin isotypes (e.g., IgA, IgM, and IgG) associated with an immune response to SARS-CoV-2 infection or vaccination. Assays were accomplished using a flow-based, multiplex fluorescent reader with dual-channel capability. Optimizations focused on analyte capture time, detection antibody concentration, and detection antibody incubation time. Analytical assay performance characteristics (e.g., assay range (including lower and upper limits of quantitation); and intra- and inter-assay precision) were established for either IgG/IgM or IgA/IgM serotype combination in tandem using the 'dual channel' mode. Analyte capture times of 30 min for IgG, 60 min for IgM, and 120 min for IgA were suitable for most applications, providing a balance of assay performance and throughput. Optimal detection antibody incubations at 4 µg/mL for 30 min was observed and are recommended for general applications, given the overall excellent precision (percent coefficient of variance (%CV) ≤ 20%) and sensitivity values observed. The dynamic range for the IgG isotype spanned several orders of magnitude for each assay (Spike S1, Nucleocapsid, and Membrane glycoproteins), which supports robust titer evaluations at a 1500 dilution factor for clinical applications. Finally, the optimized protocol was applied to monitoring Spike S1 seroconversion for subjects (n = 4) that completed a SARS-CoV-2 vaccine regimen. Within this cohort, Spike S1 IgG levels were observed to reach maximum titers at 14 days following second dose administration, at a much higher (~40-fold) signal intensity than either IgM or IgA isotypes. Interestingly, we observed highly variable Spike S1 IgG titer decay rates that were largely subject-dependent were observed, which will be the topic of future studies.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Year: 2022 Document Type: Article